CAPOX (XELOX)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-OXALIPLATIN` `DRUG-CAPECITABINE`

ID	`REG-CAPOX`
Type	Regimen
Status	reviewed 2026-04-26 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-COLON-2024` `SRC-NCCN-COLON-2025`

Notes

Patient-friendlier alternative to FOLFOX (oral fluoropyrimidine + 3-weekly oxaliplatin vs 2-weekly CIV). IDEA: 3 mo CAPOX non-inferior to 6 mo for low-risk stage III, with substantially less neuropathy. Avoid in patients who cannot reliably take PO (compliance, dysphagia).

Used By

Indication

IND-CRC-ADJUVANT-STAGE2-HIGHRISK-FOLFOX - IND-CRC-ADJUVANT-STAGE2-HIGHRISK-FOLFOX
IND-CRC-ADJUVANT-STAGE3-CAPOX - IND-CRC-ADJUVANT-STAGE3-CAPOX
IND-RECTAL-TNT-SHORT-COURSE-RAPIDO - IND-RECTAL-TNT-SHORT-COURSE-RAPIDO